Amoy Diagnostics

Jan 29, 2018

AmoyDx, Medikonia Ink MDx Distribution Deal

AmoyDx's molecular diagnostics tests, powered by its ADx-ARMS and Super-ARMS technologies, will be made available in Hong Kong and Macau.

Jan 22, 2018

AmoyDx Wins Chinese Approval for Lung Cancer Liquid Biopsy CDx

The real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples.

May 16, 2017

Amoy Dx Partners With Canbridge on CDx Development

Amoy will supply its CD95 IHC and CpG2 qPCR kits to develop a companion diagnostic for Canbridge's lead product targeting recurrent glioblastoma multiforme.

Feb 03, 2017

Japan Regulators Approve AmoyDx's Lung Cancer CDx

The firm's ROS1 gene fusion kit was approved as a companion diagnostic for Pfizer's Xalkori.

Jul 28, 2016

Merck KGaA, AmoyDx Partner on Colorectal Cancer Test for Chinese Market

The test, which will be based on AmoyDx's proprietary real-time PCR technology, will identify cancer-associated mutations in the RAS gene family.

Oct 01, 2015

AmoyDx, Illumina Partner to Develop NGS Cancer Diagnostics for Chinese Clinical Oncology Market

AmoyDx will develop and commercialize a series of oncology tests that use Illumina NGS technology, including the firm's TruSight Tumor 15 panel.

Oct 24, 2014

Amoy Diagnostics Obtains CE Mark for Cancer Mutation Assays

NEW YORK (GenomeWeb) — Chinese molecular diagnostics firm Amoy Diagnostics said today that four of its mutation analysis kits have received CE marking.

Oct 17, 2014

MoBiTec to Distribute Amoy's MDx Products in Germany

NEW YORK (GenomeWeb) – MoBiTec today announced a deal for the distribution of Amoy Diagnostics products in Germany.

Sep 03, 2014

Chinese Regulators Approve AmoyDx's ALK, ROS1 Gene Fusion Detection Kits

NEW YORK (GenomeWeb) – Chinese molecular diagnostics firm Amoy Diagnostics this week announced it has received regulatory approval from the China Food and Drug Administration for two in vitro diagnostics kits.
The firm also said that the kits obtained CE marking in Europe.

Aug 29, 2013

OxOnc to Use Amoy Gene Fusion Kits in Trial of Pfizer Drug

NEW YORK (GenomeWeb News) – Amoy Diagnostics today said that it has reached an agreement with OxOnc Development to use Amoy's ROS1 Gene Fusions Detection Kits for a pivotal clinical trial of Pfizer's Xalkori (crizotinib).

Pages

Breaking News

The Scan

Not Always an Answer

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

CRISPR Acceptance or Not?

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

This Week in Science

In Science this week: research regulation and reporting requirement reform, and more.

Building Up Numbers

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.